Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/24778
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
- IOC - Artigos de Periódicos [12500]
Metadatos
Mostrar el registro completo del ítem
AN α-GAL-CONTAINING NEOGLYCOPROTEIN-BASED VACCINE PARTIALLY PROTECTS AGAINST MURINE CUTANEOUS LEISHMANIASIS CAUSED BY LEISHMANIA MAJOR
α-Galneoglycoprotein- based vaccines
Leishmania major
Autor
Afiliación
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Chemistry. Border Biomedical Research Center. El Paso, Texas, USA.
Liverpool School of Tropical Medicine. Department of Parasitology. Pembroke Place, Liverpool, United Kingdom.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Chemistry. Border Biomedical Research Center. El Paso, Texas, USA.
Liverpool School of Tropical Medicine. Department of Parasitology. Pembroke Place, Liverpool, United Kingdom.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Molecular e Doenças Endêmicas. Rio de Janeiro, RJ. Brasil.
Liverpool School of Tropical Medicine. Department of Parasitology. Pembroke Place, Liverpool, United Kingdom / Liverpool School of Tropical Medicine. Department of Vector Biology. Pembroke Place, Liverpool, United Kingdom.
University of Texas at El Paso. Department of Chemistry. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Chemistry. Border Biomedical Research Center. El Paso, Texas, USA.
Liverpool School of Tropical Medicine. Department of Parasitology. Pembroke Place, Liverpool, United Kingdom.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Chemistry. Border Biomedical Research Center. El Paso, Texas, USA.
Liverpool School of Tropical Medicine. Department of Parasitology. Pembroke Place, Liverpool, United Kingdom.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Molecular e Doenças Endêmicas. Rio de Janeiro, RJ. Brasil.
Liverpool School of Tropical Medicine. Department of Parasitology. Pembroke Place, Liverpool, United Kingdom / Liverpool School of Tropical Medicine. Department of Vector Biology. Pembroke Place, Liverpool, United Kingdom.
University of Texas at El Paso. Department of Chemistry. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
Resumen en ingles
Protozoan parasites from the genus Leishmania cause broad clinical manifestations known as leishmaniases, which affect millions of people worldwide. Cutaneous leishmaniasis (CL), caused by L. major, is one the most common forms of the disease in the Old World. There is no preventive or therapeutic human vaccine available for L. major CL, and existing drug treatments are expensive, have toxic side effects, and resistant parasite strains have been reported. Hence, further therapeutic interventions against the disease are necessary. Terminal, non-reducing, and linear α-galactopyranosyl (α-Gal) epitopes are abundantly found on the plasma membrane glycolipids of L. major known as glycoinositolphospholipids. The absence of these α-Gal epitopes in human cells makes these glycans highly immunogenic and thus potential targets for vaccine development against CL.
Palabras clave en ingles
cutaneous leishmaniasisα-Galneoglycoprotein- based vaccines
Leishmania major
Compartir